What people say

" The emergence of alternative funding sources for UK ventures, and the rise of AIM as a market makes financing more complex. Companies need advisors like 4D who really know their way around. "

Translational medicine, biomarkers and personalised medicine

The drug discovery and development process is undergoing radical change.

• Regulators, research councils, charities and pharma companies are committing increasing priority and resource to a new type of (‘translational’) study between traditional discovery and development.
• Translational medicine seeks to expose drug discovery pipelines to an intense dose of clinical scrutiny based on clinical insight, tissue samples, pharmacogenomics, patient data bio-informatics.
• Powerful new biomarkers are being identified which will enable far greater powers of disease prediction and treatment efficacy and toxicology.

This development has potentially major implications:

• Demand for new technologies (microprocessing, imaging)
• Major new biomarker licensing and product development opportunities
• New markets for niche medicines
• Ultimately the rise of personalised predictive medicine, and
• The growth of major consumer healthcare ‘wellness’ market

In 2005 we carried out a major research project into translational medicine collaborations around the world, and subsequently advised on the $50m biomarker collaboration recently announced by Wyeth (see case study).

Contact us to find out more about how we could help you…

‹ Back to list